Innovation Pharmaceuticals Inc (IPIX)

[mdphd2008]

Govorchin your frustration with the inability of patients to benefit from IPIX drugs are slightly misdirected. The FDA is the gatekeeper. Brilacidin phase 3 for ABSSI has potentially been held up because of their lack of appreciation as to the necessity for a new antibiotic. My assumptions based on reading between the lines, is that they are making the phase 3 trial more rigorous and expensive than it requires. As a physician, I can say that medicine is always a balance between benefit vs. risk. I bring up this pointy today, because yesterday’s PR I suspect was a message to the IBD community that IPIX plans to approach the FDA to expand the platform and they are hoping the FDA doesn’t make the trials to difficult and expensive. The IBD community will hopefully lobby and pressure the FDA to not obstruct IPIX and it’s desire to help patients (and investors) by getting Brilacidin to market.